Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study-Reference-Cited by-同舟云学术

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study

Published:2020-08-06 Issue:1 Volume:147 Page:287-293
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Kashiwabara Kosuke^ORCID,Fujii Shinji,Tsumura Shinsuke,Sakamoto Kazuhiko

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-020-03344-1.pdf

Reference16 articles.

1. Asami K et al (2011) Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano lung cancer research group study. Clin Lung Cancer 12(6):387–392

2. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

3. “Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial | JNCI: Journal of the National Cancer Institute | Oxford Academic.” [Online]. Available: https://academic.oup.com/jnci/article/95/5/362/2520632. [Accessed 19May 2020]

4. Corre R et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small cell lung cancer: The Phase III randomized ESOGIA-GFPC-GECP 08–02 Study. J Clin Oncol 34(13):1476–1483

5. Ebi N et al (2008) A phase II trial of gefitinib monotherapy in Chemotherapy-Naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 3(10):1166–1171

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review;Cureus;2023-01-12

2. Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study;Journal of Pharmaceutical Health Care and Sciences;2022-12-01

3. The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation;Frontiers in Oncology;2022-05-13

4. International consensus on severe lung cancer—the first edition;Translational Lung Cancer Research;2021-06

5. Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2020-11-22